---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008457"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:49:06.192527+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ORIC Pharma reports Q4 2022 cash of $228.2M; Pfizer invests $25M; Phase 1b data expected H2 2023

## Summary
- Cash and investments $228.2M at Dec 31, 2022; runway into first half of 2025.
- Pfizer purchased 5.4M shares at $4.65/share for $25M equity investment; collaboration on ORIC-533 + elranatamab combo.
- R&D expenses $16.3M in Q4 2022 vs $16.7M in Q4 2021; full-year R&D $61.7M vs $56.9M.
- Initial Phase 1b data for ORIC-533, ORIC-114, and ORIC-944 expected in second half of 2023.
- Selected a PLK4 inhibitor development candidate; Jeff Settleman (Pfizer) joined Scientific Advisory Board.

## SEC filing metadata
- accession: 0000950170-23-008457
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017023008457/0000950170-23-008457-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017023008457/oric-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008457
- JSON: https://secwatch.observer/filing/0000950170-23-008457.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008457.txt

## Key facts
- Earnings Releases
  Oric Pharmaceuticals, Inc. reported financial results for fourth quarter and full year ended December 31, 2022.
  - Period: fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796280/000095017023008457/0000950170-23-008457-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.